HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Neuro-oncologists seek balance between optimism, realism amid promising immunotherapy data
• Anemia associated with Alinia monotherapy when used longer than FDA-approved duration Roula Baroudi, MD; Marquetta Flaugher, PhD, ARNP; Edward Grace, PharmD
• Modest improvements in lung cancer carry steep costs, but potential solutions exist Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Nuwiq for treatment of hemophilia A
• FDA approves Lonsurf for refractory metastatic colorectal cancer
• FDA grants breakthrough therapy designation, priority review to Opdivo for nonsquamous NSCLC
• FDA grants breakthrough therapy designation to ACE910 for hemophilia A
• FDA grants priority review to daratumumab for refractory, pretreated multiple myeloma
• FDA grants priority review to elotuzumab for multiple myeloma
• Fatigue, weakness during melanoma treatment Nadine E. Palermo, DO; Stephanie L. Lee, MD, PhD, ECNU
• Patients with RA may be at greater risk for developing lung cancer, lymphoma
• Additional radiotherapy safe, effective for recurrent head, neck cancer
• AGA recommends testing all patients with CRC for Lynch syndrome
• Age at menarche influences breast cancer risk in black women
• ASCO: Proposed Medicare Physician Fee Schedule does not consider cancer care costs
• Biomarker panel predicts poor prognosis in early-stage lung cancer
• Cancer survivors may face challenges during adoption process
• Cardiac toxicity low among patients treated with adjuvant trastuzumab
• CDC: Smokeless tobacco use on rise among high school athletes
• CTC, LDH biomarker panel serves as surrogate for prostate cancer survival
• Differentiated thyroid cancer recurrence rates low after initial therapy
• Dose-escalated radiation improves survival in intermediate- and high-risk prostate cancer
• E-cigarette use among adolescents leads to traditional cigarette use
• False-positive NIPT results may be due to presence of maternal malignancies
• Glyburide therapy may increase cancer risk
• Haploidentical BMT appears safe, effective for older patients with hematologic malignancies
• Hemophilia therapies drive outpatient pharmacy costs for publicly insured children
• Imatinib plus reduced-intensity chemotherapy shows promise for Ph+ALL
• Low risk of lymph node metastasis found in cutaneous head, neck SCC
• Mammography screening associated with increase in small breast cancers
• Menarche age, parity influence endometrial cancer risk for women with Lynch syndrome
• MicroRNA panel may help identify malignant pancreatic lesions
• Microscopic vascular invasion predicts poor outcomes for patients with NSCLC
• NCI-MATCH to assess treatments based on genetic abnormalities, not cancer type
• Neoadjuvant chemoradiotherapy benefits patients with esophageal, esophagogastric junction cancers
• Newer oral contraceptive combinations associated with higher VTE risk
• Nexavar, TACE well tolerated in elderly patients with HCC
• Novel immunosuppression triplet confers positive results in primary ITP
• Solid predominant subtype of early-stage lung cancer predicts recurrence, post-recurrence survival
• TKIs appear safe for patients with CML
• Tumor depth, diameter predict SLN status, survival in Merkel cell carcinoma
• Conquer Cancer Foundation honors community practices
• Immunologist wins medical research award
• Myeloma expert joins Tisch Cancer Institute at Mount Sinai
• Pancreatic Cancer Action Network advisory board elects new chair
• Vanderbilt appoints hematology/oncology division director
• Adjuvant radiotherapy may prolong survival for elderly women with triple-negative breast cancer
• Cabozantinib demonstrates efficacy for advanced kidney cancer
• Genetic alterations may predict breast cancer recurrence, metastases
• Greater MET/CEP7 expression may predict therapy response in NSCLC
• Incidence of NSCLC has more than doubled among nonsmokers
• Local administration of CpG-B prolongs RFS in early-stage melanoma
• Protein biomarker may predict immunotherapy response in metastatic melanoma